
|Articles|April 15, 2022
Pfizer/BioNTech show high immune response in a booster dose against Omicron in clinical trial for children 5-11 years
Author(s)Lois Levine, MA
Pfizer/BioNTech announce positive results for a third dose of their COVID-19 vaccine for children
Advertisement
Grant Paulsen, MD, assistant professor, Division of Infectious Disease, Department of Pediatrics, Cincinnati Children's Hospital Medical Center in Ohio, and primary investigator for the hospital's clinical trial for a third dose (booster) for the Pfizer/BioNTech vaccine for COVID-19, discusses what the data might mean for children aged 5 to 11 years.
Newsletter
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Experts urge for more research into youth-onset diabetes
2
Experts discuss key clinical signs to help identify sepsis risk in young infants
3
Which children are most at risk for food allergy? New meta-analysis offers answers
4
Neurodevelopmental disorders common after infant heart surgery
5




